A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Neuroscience

• Publication date

  2015-05-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nn.4014PMID 25938884
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of regulatory variation in complex traits and disease

  2015cited by this paper
• Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain

  2013cited by this paper
• Detecting Rare Variant Effects Using Extreme Phenotype Sampling in Sequencing Association Studies

  2013cited by this paper
• Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.

  2012cited by this paper
• Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis

  2012cited by this paper
• Sp1 Regulates Human Huntingtin Gene Expression

  2012cited by this paper
• Huntington's disease: from molecular pathogenesis to clinical treatment

  2011cited by this paper
• Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.

  2011cited by this paper
• Oligonucleotide therapeutic approaches for Huntington disease.

  2011cited by this paper
• Family-based designs for genome-wide association studies

  2011cited by this paper
• CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches

  2010cited by this paper
• Variation in Transcription Factor Binding Among Humans

  2010cited by this paper
• Age at onset in Huntington’s disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7

  2010cited by this paper
• Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia

  2010cited by this paper
• Comparing Transcription Rate and mRNA Abundance as Parameters for Biochemical Pathway and Network Analysis

  2010cited by this paper
• The gene coding for PGC-1α modifies age at onset in Huntington's Disease

  2009cited by this paper
• Global patterns of cis variation in human cells revealed by high-density allelic expression analysis

  2009cited by this paper
• Allele‐specific silencing of mutant Huntington’s disease gene

  2009cited by this paper
• 4p16.3 haplotype modifying age at onset of Huntington disease

  2009cited by this paper
• Sustained effects of nonallele‐specific Huntingtin silencing

  2009cited by this paper
• Huntington's disease: the case for genetic modifiers

  2009cited by this paper
• Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

  2009cited by this paper
• Identifying modifier genes of monogenic disease: strategies and difficulties

  2008cited by this paper
• Mechanisms of neurodegeneration in Huntington’s disease

  2008cited by this paper
• Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease.

  2008cited by this paper
• Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

  2007cited by this paper
• In Silico Detection of Sequence Variations Modifying Transcriptional Regulation

  2007cited by this paper
• Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.

  2006cited by this paper
• p53 tumor suppressor protein regulates the levels of huntingtin gene expression

  2006cited by this paper
• Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease

  2006cited by this paper
• Proteomics for the early detection and treatment of hepatocellular carcinoma

  2006cited by this paper
• Wild‐type huntingtin protects neurons from excitotoxicity

  2006influential reference
• Body weight is modulated by levels of full-length huntingtin.

  2006cited by this paper
• RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

  2005cited by this paper
• Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.

  2005cited by this paper
• Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

  2005cited by this paper
• Physiological functions for brain NF-kappaB.

  2005cited by this paper
• Physiological functions for brain NF-κB

  2005cited by this paper
• JASPAR: an open-access database for eukaryotic transcription factor binding profiles

  2004cited by this paper
• Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

  2004cited by this paper
• Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol

  2004cited by this paper
• Mosaicism of the CAG repeat sequence in the Huntington disease gene in a pair of monozygotic twins

  2004cited by this paper
• A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length

  2004cited by this paper
• Structure of NF-kappaB p50/p65 heterodimer bound to the PRDII DNA element from the interferon-beta promoter.

  2002cited by this paper
• Structure of NF-κB p50/p65 Heterodimer Bound to the PRDII DNA Element from the Interferon-β Promoter

  2002cited by this paper
• Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease.

  2002cited by this paper
• A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus.

  2001cited by this paper
• ST14A cells have properties of a medium-size spiny neuron.

  2001cited by this paper
• Modifier genes in mice and humans

  2001cited by this paper
• Loss of normal huntingtin function: new developments in Huntington's disease research.

  2001influential reference
• Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.

  2001cited by this paper
• Generation and characterization of embryonic striatal conditionally immortalized ST14A cells

  1998cited by this paper
• Functional analysis of the Huntington's disease (HD) gene promoter.

  1998cited by this paper
• Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA

  1998cited by this paper
• Isolation and characterization of the rat huntingtin promoter.

  1998cited by this paper
• Analysis of the 5' upstream sequence of the Huntington's disease (HD) gene shows six new rare alleles which are unrelated to the age at onset of HD.

  1997cited by this paper
• The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.

  1997cited by this paper
• Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease.

  1997cited by this paper
• Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B.

  1996cited by this paper
• Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype.

  1996cited by this paper
• Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes.

  1995cited by this paper
• A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing.

  1994cited by this paper
• The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

  1993cited by this paper
• Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues

  1993cited by this paper
• Huntington's disease gene (IT15) is widely expressed in human and rat tissues.

  1993cited by this paper
• Morphometric analysis of the prefrontal cortex in Huntington's disease

  1991influential reference
• An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

  1990cited by this paper
• Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis

  1988cited by this paper

• Pathogenesis of polyglutamine diseases: Piecing together a complex molecular puzzle.

  2026cites this paper
• DNA Methylation Status of Regulatory Regions of Apoptosis-Associated Genes in Dystropy «Huntington’s Disease—Non-Small Cell Lung Cancer»

  2025cites this paper
• HTT loss-of-function contributes to RNA deregulation in developing Huntington’s disease neurons

  2025cites this paper
• Biallelic genome engineering to create isogenic induced pluripotent stem cells modelling Huntington's disease.

  2025cites this paper
• Ascertainment of uninterrupted CAG repeat length and disease-modifying variants in fragment-based genetic testing for Huntington Disease

  2024cites this paper
• Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease

  2024cites this paper
• Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT

  2024cites this paper
• Translational Approach Using Advanced Therapy Medicinal Products for Huntington's Disease.

  2024cites this paper
• Huntingtin loss-of-function contributes to transcriptional deregulation in Huntington’s disease

  2024cites this paper
• The regulating effect of curcumin on NF-κB pathway in neurodegenerative diseases: a review of the underlying mechanisms

  2024cites this paper
• A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system

  2024cites this paper
• Disruption of the nascent polypeptide-associated complex leads to reduced polyglutamine aggregation and toxicity

  2024cites this paper
• Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions

  2024cites this paper
• Epigenetic editing for autosomal dominant neurological disorders

  2024cites this paper
• Fueling neurodegeneration: metabolic insights into microglia functions

  2024cites this paper
• Regulation of HTT mRNA Biogenesis: The Norm and Pathology

  2024influential citation
• Stereopure ASOs: An unanticipated increase in selectivity for targeting mutant HTT

  2024cites this paper
• Triaging between post-translational modification of cell cycle regulators and their therapeutics in neurodegenerative diseases.

  2023cites this paper
• A programmable dual-targeting di-valent siRNA scaffold supports potent multi-gene modulation in the central nervous system

  2023cites this paper
• Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot–Marie–Tooth type 2A

  2023cites this paper
• Huntingtin CAG-expansion mutation results in a dominant negative effect

  2023cites this paper
• Gelation of cytoplasmic expanded CAG RNA repeats suppresses global protein synthesis

  2023cites this paper
• Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration

  2023cites this paper
• HD mutation results in a dominant negative effect on HTT function

  2023cites this paper
• Identification of quantitative trait loci and candidate genes for seed folate content in soybean

  2023cites this paper
• Loss of CAA interruption and intergenerational CAG instability in Chinese patients with Huntington’s disease

  2023cites this paper
• Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases

  2023cites this paper
• Novel Haplotype in the HHEX Gene Promoter Associated with Body Length in Pigs

  2023cites this paper
• Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models

  2023cites this paper
• Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease

  2022influential citation
• IKKβ signaling mediates metabolic changes in the hypothalamus of a Huntington disease mouse model

  2022cites this paper
• IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway

  2022cites this paper
• “Mendelian Code” in the Genetic Structure of Common Multifactorial Diseases

  2022cites this paper
• Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases

  2022influential citation
• PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington’s disease

  2022cites this paper
• CRISPR base editing of cis-regulatory elements enables the perturbation of neurodegeneration-linked genes.

  2022cites this paper
• A pathogenic proteolysis–resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function

  2022cites this paper
• A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry

  2022cites this paper
• Alternative processing of human HTT mRNA with implications for Huntington’s disease therapeutics

  2022cites this paper
• Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.

  2022cites this paper
• A Functional Variant in the Aquaporin-3 Promoter Modulates Its Expression and Correlates With Resistance to Porcine Epidemic Virus Infection in Porcine Intestinal Epithelial Cells

  2022cites this paper
• The Mystery of EVP4593: Perspectives of the Quinazoline-Derived Compound in the Treatment of Huntington’s Disease and Other Human Pathologies

  2022cites this paper
• CRISPR base editing of cis-regulatory elements enables target gene perturbations

  2022cites this paper
• Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic

  2022cites this paper
• IKKβ signaling mediates metabolic changes in the hypothalamus of a Huntington’s disease mouse model

  2021cites this paper
• The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington’s Disease: A Historical Perspective

  2021cites this paper
• Biomarkers in Huntington’s

  2021cites this paper
• Non-Cell Autonomous and Epigenetic Mechanisms of Huntington’s Disease

  2021cites this paper
• Huntingtin and the Synapse

  2021cites this paper
• STIM2 Mediates Excessive Store-Operated Calcium Entry in Patient-Specific iPSC-Derived Neurons Modeling a Juvenile Form of Huntington's Disease

  2021cites this paper
• Increasing brain palmitoylation rescues behavior and neuropathology in Huntington disease mice

  2021cites this paper
• Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

  2020cites this paper
• Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease

  2020cites this paper
• A brief history of human disease genetics

  2020cites this paper
• Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.

  2020cites this paper
• Genome resequencing reveals demographic history and genetic architecture of seed salinity tolerance in Populus euphratica

  2020cites this paper
• Mitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling

  2020cites this paper
• Cell cycle re-entry of neurons and reactive neuroblastosis in Huntington's disease: Possibilities for neural-glial transition in the brain.

  2020cites this paper
• Identification of genetic factors underpinning phenotypic heterogeneity in Huntington's disease and other neurodegenerative disorders

  2020cites this paper
• Genetic testing in dementia — utility and clinical strategies

  2020cites this paper
• Huntington’s disease onset is determined by length of uninterrupted CAG, not encoded polyglutamine, and is modified by DNA maintenance mechanisms

  2019cites this paper
• A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes

  2019cites this paper
• Investigation of the variants at the binding site of inflammatory transcription factor NF-κB in patients with end-stage renal disease

  2019cites this paper
• Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.

  2019cites this paper
• Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.

  2019cites this paper
• IKKβ slows Huntington’s disease progression in R6/1 mice

  2019cites this paper
• Cellular Specificity of NF-κB Function in the Nervous System

  2019cites this paper
• Length of uninterrupted CAG repeats, independent of polyglutamine size, results in increased somatic instability and hastened age of onset in Huntington disease

  2019cites this paper
• The effects of huntingtin-lowering: what do we know so far?

  2019cites this paper
• Enhanced Na+‐K+‐2Cl‐ cotransporter 1 underlies motor dysfunction in huntington's disease

  2019cites this paper
• Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.

  2019cites this paper
• Synapse-to-Nucleus Signaling in Neurodegenerative and Neuropsychiatric Disorders.

  2019cites this paper
• A Pipeline to Assess Disease-Associated Haplotypes in Repeat Expansion Disorders: The Example of MJD/SCA3 Locus

  2019cites this paper
• CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease Onset

  2019cites this paper
• Brain Microbiota in Huntington’s Disease Patients

  2019cites this paper
• Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease

  2019cites this paper
• Gene Therapies for Polyglutamine Diseases.

  2018cites this paper
• Production of Wilson Disease Model Rabbits with Homology-Directed Precision Point Mutations in the ATP7B Gene Using the CRISPR/Cas9 System

  2018cites this paper
• Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders

  2018cites this paper
• Transcriptional Regulation of the Huntingtin Gene

  2018cites this paper
• Genetic modifiers of age-at-onset in polyglutamine diseases.

  2018cites this paper
• Computational Analysis of Transcriptional Regulation Sites at the HTT Gene Locus

  2018cites this paper
• Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies

  2018cites this paper
• RNA Related Pathology in Huntington's Disease.

  2018cites this paper
• Maladie de Huntington : aspects diagnostiques actuels et applications pratiques

  2018cites this paper
• Murine Models of Huntington's Disease for Evaluating Therapeutics.

  2018cites this paper
• Using Genomic Data to Find Disease-Modifying Loci in Huntington's Disease (HD).

  2018cites this paper
• The Danish HD Registry—a nationwide family registry of HD families in Denmark

  2017cites this paper
• Amplification-free, CRISPR-Cas9 Targeted Enrichment and SMRT Sequencing of Repeat-Expansion Disease Causative Genomic Regions

  2017cites this paper
• From huntingtin gene to Huntington’s disease-altering strategies

  2017cites this paper
• Epidemiology of Huntington disease.

  2017cites this paper
• Genetic variation in neurodegenerative diseases and its accessibility in the model organism Caenorhabditis elegans

  2017cites this paper
• Huntington’s Disease: Calcium Dyshomeostasis and Pathology Models

  2017cites this paper
• Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels

  2017cites this paper
• A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease

  2017cites this paper
• The role of histone modification and a regulatory single-nucleotide polymorphism (rs2071166) in the Cx43 promoter in patients with TOF

  2017cites this paper
• Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models

  2017cites this paper
• Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch

  2017cites this paper
• Huntington’s Disease Associated Genes: Molecular Basis of Disease and Possible New Targets for Treatment

  2017cites this paper
• Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo.

  2017cites this paper